drugset
Drugs / Human Umbilical Cord-derived Mesenchymal stem cell
last change Apr 2023 re-read 3 minutes ago

Human Umbilical Cord-derived Mesenchymal stem cell

Cell therapy

Developed for
bronchopulmonary dysplasia
Investigated by
Children's Hospital of Chongqing Medical University · Children's Hospital of Fudan University

Trials 2

today NCT03645525 · Ph 1/2 NCT03601416 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03645525 Dec 2019 → Oct 2022 bronchopulmonary dysplasia Children's Hospital of Fudan University Withdrawn No outcome recorded
Phase 21 trial
Phase 2 NCT03601416 Jul 2019 → Jun 2021 bronchopulmonary dysplasia Children's Hospital of Chongqing Medical University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Human umbilical cord-derived mesenchymal stem cell “Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.” NCT03601416 ↗
1

NCT03645525 ↗
Modality Cell therapy “Stem-cell therapy is a promising way to improve lung injury and abnormal alveolarization” PMID 32005282 ↗ Jan 2020
Route Intravenous “through intravenous infusion” NCT03601416 ↗